Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open-Label, Phase 1 Study of LOR-253 HCl in Patients With Advanced or Metastatic Solid Tumours.

Next Previous
Trial Profile

Open-Label, Phase 1 Study of LOR-253 HCl in Patients With Advanced or Metastatic Solid Tumours.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 01 Dec 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs APTO 253 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; Biomarker
  • Sponsors Lorus Therapeutics

Most Recent Events

  • 24 Feb 2014 Status changed from recruiting to completed, as per ClinicalTrials.gov record.
  • 01 Oct 2013 Results have been presented at the 2013 European Cancer Congress annual meeting according to a Lorus Therapeutics media release. Results were also summarised in the media release.
  • 09 Jul 2013 Promising results reported in a Lorus Therapeutics media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top